Bristol-Myers Squibb Company (BMY) — Stock Score Summary

Bristol-Myers Squibb Company (BMY) has a MoatMap StockRank of 100/100 based on Quality (70/100), Value (62/100), and Momentum (76/100) factor scores. The current signal is STRONG BUY. While Bristol-Myers Squibb is a large, established pharmaceutical company, it does not currently align with any strong, unpriced macro inflection points creating asymmetric risk-reward for the fund, nor does it fit the 'observable demand signals' or 'scale economics with customers' criteria of Lynch or Sleep lenses.

Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines for serious diseases, primarily in oncology, immunology, cardiovascular, and hematology. Its strong research and development pipeline, coupled with a portfolio of blockbuster drugs and strategic acquisitions, provides a significant competitive moat in specialized therapeutic areas. BMY is a leading global biopharmaceutical firm known for its groundbreaking therapies and robust intellectual property portfolio.

Key Financial Metrics

Price$59.46
Market Cap$121.4B
P/E (TTM)16.33
P/E (Forward)9.45
Price/Book5.93
Return on Equity38.7%
Return on Invested Capital16.8%
Debt/Equity230.97
Gross Margin72.0%
Operating Margin33.0%
Revenue Growth2.6%
Dividend Yield4.3%
Free Cash Flow$9.9B

Bristol-Myers Squibb Company operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Bristol-Myers Squibb Company’s (BMY) StockRank?
MoatMap’s StockRank for Bristol-Myers Squibb Company (BMY) is 100/100, with a Strong Buy signal. It is a composite of Quality (70), Value (62), and Momentum (76) factor ranks across MoatMap’s 19,000+ stock universe.
Does Bristol-Myers Squibb Company have an economic moat?
Bristol-Myers Squibb Company (BMY) has a Quality factor score of 70/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Bristol-Myers Squibb Company a buy, hold, or sell?
MoatMap’s current signal for Bristol-Myers Squibb Company (BMY) is Strong Buy, based on a StockRank of 100/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Bristol-Myers Squibb Company in?
Bristol-Myers Squibb Company (BMY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (United States).
Browse all ranked stocksBMY deep dive reportAI ChampionsHow we score stocksSense-check another stock